Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $20.5 million, down from $23.1 million in the prior year, but above guidance of $18 million to $20 million due to higher shipments to China [6] - Gross margin decreased to 56.4% from 57.2% in Q2 2024, but was at the high end of guidance [6] - Adjusted operating income improved to $1 million from $800,000 in Q2 2024, and adjusted EBITDA increased to $1.5 million from $1.3 million [7][12] - Year-to-date cash flow from operations was strong at $5.7 million compared to $600,000 in the same period last year [13] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 5.4% sequentially and 11.7% year-over-year, primarily due to budget clarity issues for academic institutions [8] - European revenue increased 9% sequentially, driven by stronger academic shipments, while year-over-year revenues were largely flat [10] - APAC revenue decreased over 25% year-over-year due to tariff-related issues, with orders and shipments halting in April but gradually returning to normal [11] Market Data and Key Metrics Changes - The company’s China business accounted for about 10% of revenue, which nearly went to zero in April but has since returned to a more normal run rate [32] - NIH funding delays are extending academic purchasing cycles, but budgets remain in place, with expectations for improvement into 2026 [19] Company Strategy and Development Direction - The company aims to maintain financial discipline, accelerate product adoption, and strengthen its capital structure through refinancing [17][18] - New product pipeline includes the SOHO telemetry platform and the MeSH MEA organoid platform, which are expected to drive future growth [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of the year, believing that the worst of tariff uncertainties is behind them [19] - The company is focused on stabilizing its core business and restructuring its balance sheet to build sustainable sales and profitability [22] Other Important Information - Net debt decreased to $27.9 million from $32 million, reflecting improved operating cash flow and quarterly principal payments [14] - The company has negotiated amendments to its credit facility, providing additional time to refinance and pay down existing debt [15] Q&A Session Summary Question: What do you expect total debt to be by December 5? - The company expects debt to be around $33 million, continuing to pay down $1 million per quarter [26] Question: What are your thoughts on NIH funding and potential budget changes? - Management noted that academic purchasing cycles have been extended, but budgets remain in place, which could benefit the business if conditions improve in 2026 [30] Question: What is your current exposure to China and how did it perform in the quarter? - The China business is about 10% of revenue, which saw a significant decline in April but has returned to normal levels [32]

Market Overview - On June 16, US stock indices opened higher, with the Dow Jones, S&P 500, and Nasdaq all rising over 1% [1] - The Dow Jones index reached 42,646.75, up 1.06%, while the S&P 500 was at 6,042.23, up 1.09%, and the Nasdaq Composite at 19,684.84, up 1.43% [2] Sector Performance - Major technology stocks saw collective gains, with Meta rising nearly 3%, Nvidia up nearly 2%, and Tesla and Microsoft increasing over 1% [2] - Bank stocks also performed well, with Goldman Sachs and Citigroup both rising over 2%, while Deutsche Bank, JPMorgan, Wells Fargo, and Bank of America increased over 1% [2] - Quantum computing stocks surged, with Arqit Quantum up over 24%, Quantum Computing rising nearly 13%, D-Wave Quantum increasing over 9%, and Rigetti Computing up over 6% [2] Chinese Concept Stocks - The Nasdaq China Golden Dragon Index rose over 2%, with notable individual stock performances including Futu Holdings up over 6%, Bilibili nearly 5%, and iQIYI over 4% [3] - Xpeng Motors and Li Auto both increased over 3%, while Alibaba rose nearly 3% and JD.com and Baidu increased over 2% [3] Brain-Computer Interface Stock - The stock of Brain Rebirth surged dramatically, experiencing multiple trading halts, and was up over 328% at one point [3] - The stock opened at 26.20, reached a high of 67.09, and had a trading volume of 883,200 shares, with a market capitalization of 33.175 billion [4] - Despite the significant stock price increase, Brain Rebirth is an early-stage biotech company focused on developing traditional Chinese medicine for neurocognitive disorders, with no revenue reported from product sales from 2021 to 2024 [4]

脑机接口概念股脑再生开盘暴涨，多次熔断。 当地时间6月16日，美股三大股指全线高开，截至发稿，道指、标普500指数、纳指均涨超1%。 | 道琼斯指数 | 42646.75 | +1.06% | | --- | --- | --- | | .DJI | | | | 标普500指数 | 6042.23 | +1.09% | | .SPX | | | | 纳斯达克综合指数 | 19684.84 | +1.43% | | .IXIC | | | | 纳斯达克中国金龙指数 | 7402.42 | +2.33% | | .HXC | | | 大型科技股集体上涨，截至发稿，脸书母公司Meta涨近3%，英伟达涨近2%，特斯拉、微软涨超1%，亚马逊、苹果、谷歌A小幅上涨。 | 今开 | 26.200 | 最高 | | 67.090 | 成交量 | | 88.32万股 | 总市值 ▼ | | 331.75亿 | 市盈(TTM) | 亏损 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 昨收 | 15.661 | ...